trending Market Intelligence /marketintelligence/en/news-insights/trending/uCYzzBtNEP-xHzCqgFbZcQ2 content esgSubNav
In This List

Prometic's lung disease drug gets US FDA orphan drug designation

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Prometic's lung disease drug gets US FDA orphan drug designation

The U.S. Food and Drug Administration granted orphan drug status to ProMetic Life Sciences Inc.'s Ryplazim to treat idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis is a chronic, devastating, and ultimately fatal disease characterized by a progressive decline in lung function.

Prometic said this is the second orphan drug designation for its idiopathic pulmonary fibrosis pipeline after PBI-4050.